lenalidomide has been researched along with Opportunistic Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Mao, B; Wang, X; Xu, C; Zhang, X; Zhao, Y | 1 |
| Kambe, E; Sato, S; Tamai, Y | 1 |
1 review(s) available for lenalidomide and Opportunistic Infections
| Article | Year |
|---|---|
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunocompromised Host; Immunologic Factors; Immunosuppressive Agents; Incidence; Induction Chemotherapy; Lenalidomide; Middle Aged; Multiple Myeloma; Observational Studies as Topic; Opportunistic Infections; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2018 |
1 other study(ies) available for lenalidomide and Opportunistic Infections
| Article | Year |
|---|---|
Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Opportunistic Infections | 2019 |